Home

Biotech

Broadband

B2B Internet

Europe 2001

Internet

Internet 
Architecture

Internet 
Infrastructure

Market 2000+

Oil Services

Pharmaceutical

Regional Bank

Retail

Semiconductor

Software

Telecom

Utilities

Wireless
Watson Pharmaceuticals Inc (NYSE:WPI)9/3/2010
most recent headlinesmore headlines:       
WEDNESDAY, SEPTEMBER 01, 2010
8:00 AMWatson to Present at the Morgan Stanley Global Healthcare Unplugged Conference - PR Newswire
TUESDAY, AUGUST 31, 2010
8:00 AMScinoPharm to Invest in Tanvex Biologics - PR Newswire
FRIDAY, AUGUST 13, 2010
5:07 PMWatson Plans Q4 2010 ella(R) (ulipristal acetate) Emergency Contraceptive Launch - PR Newswire
MONDAY, AUGUST 09, 2010
10:56 AMFitch Upgrades Watson Pharmaceuticals' IDR to 'BBB'; Outlook Stable - BusinessWire
THURSDAY, AUGUST 05, 2010
7:00 AMWatson Q2 Net Revenue Climbs 29 Percent to $875 Million - PR Newswire
5:40 AMWatson Pharmaceuticals hires Sigurdur Oli Olafsson as executive vice president of global generics - M2
WEDNESDAY, AUGUST 04, 2010
8:45 AMWatson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics - PR Newswire
5:06 AMWatson Pharmaceuticals names Robert Stewart as executive vice president, global operations - M2
TUESDAY, AUGUST 03, 2010
4:15 PMWatson Promotes Robert Stewart to Executive Vice President, Global Operations - PR Newswire
THURSDAY, JULY 15, 2010
7:55 AMWatson and Itero Enter Worldwide License Agreement on Biologic Development Candidate - PR Newswire


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

HOLDRS Defined |  HOLDRS Outstanding  |  FAQ  |  Proxies by email  |  Investment Strategies
Spin-Offs & Changes  |  Current Trading  |  Download a Prospectus  |  Site Map

Merrill Lynch, Pierce, Fenner & Smith Incorporated is a registered broker-dealer and a wholly-owned subsidiary of Bank of America Corporation.
Securities Products: Are Not FDIC Insured • Are Not Bank Guaranteed • May Lose Value.

The information in this Internet site is directed at, and is intended for distribution to, and for use by, persons in the U.S. only, and is not intended for distribution to or use by any person in any other jurisdiction. Merrill Lynch does not warrant the accuracy or completeness of any price, tax, cost basis, or other information on this site, or any investment, tax or other benefits associated with HOLDRS.

The information on HOLDRSSM contained in this Internet site is solely for informational purposes and does not constitute either an offer to sell or the solicitation of an offer to buy HOLDRS. This information on HOLDRS is not, and is not intended to be, a complete discussion of all material information you should know about HOLDRS. If you are considering whether to purchase a HOLDRS security, you should carefully read the relevant prospectus prior to making a purchase. You should not rely on the information contained in this Internet site. Please view Terms of Use and Legal Notices for additional important legal information and the terms and conditions governing your use of this site.

U.S. Patent Pending.
HOLDRS and HOLding Company Depositary ReceiptS are service marks of Merrill Lynch & Co., Inc.

© Copyright 2000, Merrill Lynch, Pierce, Fenner & Smith Incorporated. Member, Securities Investor Protection Corporation (SIPC). All rights reserved.